Niagen Bioscience (NAGE) SVP and General Counsel receives 41,420 stock options

Rhea-AI Filing Summary

Lopez Carlos Luis reported acquisition or exercise transactions in this Form 4 filing.

Niagen Bioscience, Inc. reported that its SVP and General Counsel, Carlos Luis Lopez, received a grant of employee stock options covering 41,420 shares on the reported grant date. The options were awarded at no purchase price on grant and will vest in four equal annual installments on each anniversary of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lopez Carlos Luis

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Options (right to buy)	$4.94	02/19/2026		A		41,420		02/19/2027(1)	02/18/2036	Common Stock	41,420	$0	41,420	D

Explanation of Responses:

1. One-fourth of the shares subject to the option shall vest on each anniversary of the grant date.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Niagen Bioscience (NAGE) report for Carlos Luis Lopez?

Niagen Bioscience reported that SVP and General Counsel Carlos Luis Lopez received an award of employee stock options for 41,420 shares. These options were granted as part of his compensation and increase his potential future equity stake if they vest and are exercised.

How many stock options were granted to the Niagen Bioscience (NAGE) SVP and General Counsel?

Carlos Luis Lopez received employee stock options covering 41,420 shares of Niagen Bioscience common stock. This grant represents a new derivative position that was not previously held and is now reported as directly owned following the transaction.

What is the vesting schedule for the Niagen Bioscience (NAGE) options granted to Carlos Luis Lopez?

The options granted to Carlos Luis Lopez vest in four equal parts. One-fourth of the shares subject to the option will vest on each anniversary of the grant date, creating an annual vesting schedule over four years tied to continued service.

Was the Niagen Bioscience (NAGE) option grant to Carlos Luis Lopez a purchase or a compensation award?

The transaction is classified as a grant or award acquisition, not an open-market purchase. It reflects employee stock options granted as compensation at a reported price of 0.0000 per option share on the grant date.

How many Niagen Bioscience (NAGE) options does Carlos Luis Lopez own after this Form 4 transaction?

Following this reported transaction, Carlos Luis Lopez directly holds employee stock options for 41,420 shares. This total reflects the newly granted award and represents his derivative holdings as reported in the filing after the grant.